Clinical Pharmacokinetics

, Volume 25, Issue 1, pp 20–58 | Cite as

Pharmacokinetic Drug Interactions with ACE Inhibitors

  • Hiroshi Shionoiri
Review Article Pharmacokinetic Drug Interactions

Summary

Angiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly in urine require adjustment of either the dose or the interval between doses in patients with moderate to severe renal dysfunction or severe congestive heart failure. Those agents such as temocapril (CS 622) and fosinopril, excreted both in urine and bile, may not require such adjustment. Renal clearance of ACE inhibitors may be reduced and some accumulation may occur in elderly patients with mild renal dysfunction or congestive heart failure. The bioavailability of ACE inhibitors is reduced by concomitant food or antacids which may slow gastric emptying and raise gastric pH.

Pharmacokinetic interactions with ACE inhibitors are unlikely in patients receiving thiazide or loop diuretics. When ACE inhibitors are given hyperkalaemia may occur in patients with renal insufficiency, those taking potassium supplements or potassium-sparing diuretics, and in diabetic patients with mild renal impairment. While no pharmacokinetic interaction precludes use of this combination, the pharmacokinetics of some ACE inhibitors are subject to greater variability when patients also receive β-blockers. Calcium antagonists and ACE inhibitors have additive antihypertensive effects and pharmacokinetic interactions between these agents are unlikely. One report exists of a significant effect of coadministered hydralazine on the pharmacokinetics and urinary excretion of lisinopril. Data on interactions between ACE inhibitors and digitalis are contradictory. There is no evidence that the concomitant use of ACE inhibitors and digoxin is associated with an increased risk of digitalis toxicity.

ACE inhibitors are mainly excreted by glomerular filtration and renal tubular secretion. Possible interactions between ACE inhibitors and probenecid have been noted, with renal and total body clearance of ACE inhibitors being potentially reduced in the presence of probenecid. Probenecid pretreatment may enhance the pharmacodynamic response of ACE inhibitors.

Few but contradictory data exist on the effects of H2-blockers on ACE inhibitor pharmacokinetics and little information is available on interactions between ACE inhibitors and hypo-glycaemic drugs. Some case reports link ACE inhibitors with the induction of lithium toxicity. Coadministration of lithium should be undertaken with caution, and frequent monitoring of lithium concentrations is recommended with all ACE inhibitors.

Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the haemodynamic actions of ACE inhibitors. NSAIDs reduce renal excretion of ACE inhibitors, with a corresponding increase in circulating drug concentrations. There is little information available on the pharmacokinetic interaction with ACE inhibitors and cyclosporin, but caution should be employed when they are used together. Rifampicin (rifampin) may reduce the plasma ACE inhibitor concentrations and decrease the area under their plasma concentration-time curves, by enhancing the clearance of ACE inhibitors or altering their apparent volume of distribution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achari R, Maurath C, Laddu A. Combination therapy of terazosin and captopril in the treatment of essential hypertension. Abstract. Journal of Clinical Pharmacology 29: 847, 1989Google Scholar
  2. Ahmad S. Indomethacin-enalapril interaction: an alert. Southern Medical Journal 84: 411–412, 1991PubMedCrossRefGoogle Scholar
  3. Ajayi AA, Campbell BC, Meredith PA, Kelman AW, Reid JL. The effect of captopril on the reflex control heart rate: possible mechanisms. British Journal of Clinical Pharmacology 20: 17–25, 1985PubMedCrossRefGoogle Scholar
  4. Allon M, Pasque CB, Rodriguez M. Interaction of captopril and ibuprofen on glomerular and tubular function in humans. American Journal of Physiology 259: F233–F238, 1990aPubMedGoogle Scholar
  5. Allon M, Pasque CB, Rodriguez M. Sodium and water excretion in nephrotic patients: effects of changes in renal hemodynamics. Clinical Science 79: 123–129, 1990bPubMedGoogle Scholar
  6. Antonaccio MJ, Kerwin L. Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR: implication of vascular angiotensin-II in hypertension and antihypertensive actions of captopril. Hypertension 3 (Suppl. 1): 154–162, 1981Google Scholar
  7. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. American Journal of Medicine 89: 811–813, 1990PubMedCrossRefGoogle Scholar
  8. Association of the British Pharmaceutical Industry. Innovace: ABPI data sheet compendium 1988–1989, pp. 947–949, Data-pharm Publications, London, 1988Google Scholar
  9. Atkinson AB, Brown JJ, Lever AF. Neurological dysfunction in two patients receiving captopril and cimetidine. Lancet 2: 36. 1980PubMedCrossRefGoogle Scholar
  10. Baba T, Tomiyama T, Takebe K. Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha 1-blockcr. New England Journal of Medicine 322: 1237, 1990PubMedGoogle Scholar
  11. Baez MA, Woo-Ming RB, Garg DC, Shapse DB, Deitch MW, et al. Dose-ranging study to delineate the additive antihypertensive effect of guanabenz and captopril. Journal of Clinical Pharmacology 31: 312–317, 1991PubMedGoogle Scholar
  12. Bainbridge AD, MacFadyen RJ, Lees KR, Reid JL. A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects. British Journal of Clinical Pharmacology 31: 148–153, 1991PubMedCrossRefGoogle Scholar
  13. Baldwin CM, Safferman AZ. A case of lisinopril-induced lithium toxicity. DICP: Annals of Pharmacotherapy 24: 946–947, 1990PubMedGoogle Scholar
  14. Beermann B. Pharmacokinetics of lisinopril. American Journal of Medicine 85 (Suppl. 3B): 25–30, 1988PubMedCrossRefGoogle Scholar
  15. Bellet M, Sassano P, Guyenne T, Corvol P, Menard J. Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. British Journal of Clinical Pharmacology 24: 465–472, 1987PubMedCrossRefGoogle Scholar
  16. Belz GG, Breithaupt K, Erb K, Kleinbloesem CH, Wolf GK. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension. Journal of Hypertension 7: 817–824, 1989PubMedCrossRefGoogle Scholar
  17. Belz GG, Essig J, Kleinbloesem CH, Hoogkamer JFW, Wiegand UW, et al. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. British Journal of Clinical Pharmacology 26: 547–556, 1988PubMedCrossRefGoogle Scholar
  18. Bentdsen F, Henriksen JH. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. Journal of Human Hypertension 3 (Suppl. 1): 139–145, 1989Google Scholar
  19. Berne C. Metabolic effects of ACE inhibitors. Journal of Internal Medicine 229 (Suppl. 2): 119–125, 1991Google Scholar
  20. Biour M, Jeunne C, Hugues FC, Cheymol G. Diclofenac et toux induite par les inhibiteurs de l’enzyme de conversion. Thérapie 43: 122–123, 1988PubMedGoogle Scholar
  21. Braunwald E. ACE inhibitors — a cornerstone of the treatment of heart failure. New England Journal of Medicine 325: 351–353, 1991PubMedCrossRefGoogle Scholar
  22. Brouwer RML, Bolli P, Erne P, Conen D, Kiowski W, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): s88–s91, 1985PubMedCrossRefGoogle Scholar
  23. Brown CL, Backjouse CI, Grippat JC, Santoni JPh. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. European Journal of Clinical Pharmacology 39: 327–332, 1990PubMedCrossRefGoogle Scholar
  24. Burnier M, Biollaz J. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy. Clinical Pharmacokinetics 22: 375–384, 1992PubMedCrossRefGoogle Scholar
  25. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. Journal of the American Medical Association 259: 539–544, 1988CrossRefGoogle Scholar
  26. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Journal of the American College of Cardiology 2: 755–763, 1983CrossRefGoogle Scholar
  27. Cleland JGF. ACE inhibitors in mild heart failure: first-line or second-line therapy? European Heart Journal 11 (Suppl. D): 53–57, 1990PubMedGoogle Scholar
  28. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson JIS, et al. Captopril in heart failure: a double-blind control trial. British Heart Journal 52: 530–535, 1984PubMedCrossRefGoogle Scholar
  29. Cleland JGF, Dargie HJ, Pettigrew A, Gillen G, Robertson JIS. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. American Heart Journal 112: 130–135, 1986PubMedCrossRefGoogle Scholar
  30. Cleland JGF, Henderson E, McLenachan J, Findlay IN, Dargie HJ. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. Journal of the American College of Cardiology 17: 733–739, 1991PubMedCrossRefGoogle Scholar
  31. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, et al. Comparison of enarapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 325: 303–310, 1991PubMedCrossRefGoogle Scholar
  32. Conrad AJ. ACE inhibitors and lithium toxicity. Biological Therapies in Psychiatry 11: 43, 1988Google Scholar
  33. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS]. New England Journal of Medicine 316: 1429–1435, 1987CrossRefGoogle Scholar
  34. Costa FV, Borghi C, Boschi S, Ambrosioni E. Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects on metabolic values and intracellular electrolytes. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): s70–s76, 1985PubMedCrossRefGoogle Scholar
  35. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, et al. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. New England Journal of Medicine 308: 377–381, 1983PubMedCrossRefGoogle Scholar
  36. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. American Journal of Hypertension 5: 95–110, 1992PubMedGoogle Scholar
  37. Daly P, Mettauer B, Rouleau JL, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 71: 317–325, 1985PubMedCrossRefGoogle Scholar
  38. Dargie HJ, Ray SG. The effects of angiotensin converting enzyme inhibition on coronary blood flow and infarct size limitation. Journal of Human Hypertension 3 (Suppl. 1): I–101–I–106, 1989Google Scholar
  39. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, et al. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). American Journal of Cardiology 59: 70D–78D, 1987PubMedCrossRefGoogle Scholar
  40. De Lepeleire I, Van Hecken A, Verbesselt R, Kaiser G, Barner A, et al. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers. European Journal of Clinical Pharmacology 34: 465–468, 1988PubMedCrossRefGoogle Scholar
  41. Doering W, Maass L, Irmisch R, Konig E. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. American Journal of Cardiology 59: 60D–64D, 1987PubMedCrossRefGoogle Scholar
  42. Donnelly R, Elliott HL, Meredith PA. Counter-regulatory effects of combined ACE inhibition and calcium antagonist. British Journal of Clinical Pharmacology 25: 525, 1988PubMedCrossRefGoogle Scholar
  43. Donnelly R, Elliott HL, Meredith PA, Reid JL. Enalapril in essential hypertension: The comparative effects of additional placebo, nicardipine and chlorthalidone. British Journal of Clinical Pharmacology 24: 842–845, 1987PubMedCrossRefGoogle Scholar
  44. Donnelly R, Elliott HL, Reid JL. Nicardipine combined with enalapril in patients with essential hypertension. British Journal of Clinical Pharmacology 22: 283s–287s, 1986CrossRefGoogle Scholar
  45. Douste-Blazy P, Blanc M, Montastruc JL, Conte D, Cotonat J, et al. Is there any interaction between digoxin and enalapril? British Journal of Clinical Pharmacology 22: 752–753, 1986aPubMedCrossRefGoogle Scholar
  46. Douste-Blazy P, Rostin M, Livaek B, Tordjman E, Montastruc JL, et al. Angiotensin converting enzyme inhibitors and lithium treatment. Lancet 1: 1448, 1986bPubMedCrossRefGoogle Scholar
  47. Drouet A, Bouvet O. Lithium et inhibiteurs de l’enzyme de conversion. L’Encéphale 16: 51–52, 1990PubMedGoogle Scholar
  48. Duchin KL, McKinstry DN, Cohen AI, Migdalof BM. Pharmacokinetics of captopril in healthy subjects and patients with cardiovascular diseases. Clinical Pharmacokinetics 14: 241–259, 1988PubMedCrossRefGoogle Scholar
  49. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clinical Pharmacology and Therapeutics 32: 452–458, 1982Google Scholar
  50. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (Suppl. 1): I–4–I–13, 1988Google Scholar
  51. Editorial. Guidelines for the management of mild hypertension: memorandum from a WHO/ISH Meeting. Journal of Hypertension 7: 689–693, 1989Google Scholar
  52. Fahmy NR, Gavras HP. Impact of captopril on hemodynamic and humoral effects of nitroprusside. Journal of Cardiovascular Pharmacology 7: 869–874, 1985PubMedCrossRefGoogle Scholar
  53. Fernere M, Lachkar H, Richard JL, Bringer J, Orsetti A, et al. Captopril and insulin sensitivity. Annals of Internal Medicine 102: 134–135, 1985Google Scholar
  54. Ferry JJ, Centnarowski AB, Sedman AJ, Thomas RW, Horvath AM. Multiple-dose cimctidine administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (CI-928). Journal of Clinical Pharmacology 28: 48–51, 1988PubMedGoogle Scholar
  55. Ferry JJ, Sedman AJ, Hengy H, Horvath AM. Blake DS, et al. Concomitant multiple dose quinapril administration does not alter the steady-state pharmacokinetics of digoxin. Abstract. Pharmacological Research 4: s98, 1987CrossRefGoogle Scholar
  56. Foult J-M, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation 77: 337–344, 1988PubMedCrossRefGoogle Scholar
  57. Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, et al. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to mod-crate hypertension. Cardiovascular Drugs and Therapy 3: 319–325, 1989PubMedCrossRefGoogle Scholar
  58. Gomez HJ, Cirillo VJ, Irvin JD. Enalapril: a review of human pharmacology. Drugs 30 (Suppl. 1): 13–24, 1985PubMedCrossRefGoogle Scholar
  59. Griffin JH, Hahn SM. Lisinopril-induced lithium toxicity. DICP: Annals of Pharmacotherapy 25: 101, 1991PubMedGoogle Scholar
  60. Guazzi MD, De Cesare N, Galli C, Salvioni A, Tramontana C, et al. Calcium-channel blockade with nifedipine and angiotensin-converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation 70: 279–284, 1984PubMedCrossRefGoogle Scholar
  61. Hakas JF, O’Hollaren MT, Porter GA. Topical capsaicin induces cough in patient receiving ACE inhibitor. Annals of Allergy 65: 322–323, 1990PubMedGoogle Scholar
  62. Hall D, Zeitler H, Schwarz A, Rudolph W. In congestive heart failure, aspirin counteracts the beneficial hemodynamic effects of enalapril. Abstract. Circulation 82 (Suppl. 3): 111–317, 1990Google Scholar
  63. Hansen JF, Hesse B, Christensen NJ. Enhanced sympathetic nervous activity after intravenous propranolol in ischemic heart disease. Plasma adrenaline, splanchnic blood flow and mixed venous oxygen saturation at rest and during exercise. European Journal of Clinical Investigation 8: 31–36, 1978PubMedCrossRefGoogle Scholar
  64. Hawkins MM, Seelig CB. A case of acute renal failure induced by the co-administration of NSAIDs and captopril. North Carolina Medical Journal 51: 291–291, 1990PubMedGoogle Scholar
  65. Helgeland A, Strommen R, Hagelund C, Tretuli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. Lancet 1: 872–875, 1986PubMedCrossRefGoogle Scholar
  66. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in haemodialysis patients. American Journal of Nephrology 4: 355–360, 1984PubMedCrossRefGoogle Scholar
  67. Horvath AM, Blake DS, Ferry JJ, Sedman AJ, Colburn WA. Propranolol does not influence quinapril pharmacokinetics in healthy volunteers. Abstract. Journal of Clinical Pharmacology 27: 719, 1987aGoogle Scholar
  68. Horvath AM, Ferry JJ, Sedman AJ, Colburn WA. Lack of a quinapril-hydrochlorothiazide pharmacokinetic drug interaction in healthy volunteers. Abstract. Journal of Clinical Pharmacology 27: 720, 1987bGoogle Scholar
  69. Horvath AM, Pilon D, Gaille G, Colburn WA, Ferry JJ, et al. Multiple-dose propranolol administration does not influence single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat). Biopharmaceutics and Drug Disposition 11: 191–196, 1990CrossRefGoogle Scholar
  70. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal-artery stenosis in a solitary kidney. New England Journal of Medicine 308: 373–376, 1983PubMedCrossRefGoogle Scholar
  71. Ikram H, Low CJS, Shirlaw T, Webb CM, Richards AM, et al. Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris. American Journal of Cardiology 66: 164–167, 1990PubMedCrossRefGoogle Scholar
  72. Johns DW, Ayers CR, Williams SC. Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients. Hypertension 6: 545–550, 1984PubMedCrossRefGoogle Scholar
  73. Johnson BF, Wilson J, Johnson J, Flemming J. Digoxin pharmacokinetics and spirapril, a new ACE inhibitor. Journal of Clinical Pharmacology 31: 527–530, 1991PubMedGoogle Scholar
  74. Johnson VG, Romanoff ME, Flacke JW. Case conference. Journal of Cardiothoracic and Vascular Anesthesia 5: 175–180, 1991PubMedCrossRefGoogle Scholar
  75. Johnsson G, Regårdh CC. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clinical Pharmacokinetics 1: 233–263, 1976PubMedCrossRefGoogle Scholar
  76. Joint National Committee. The 5th report on detection, evaluation and treatment of high blood pressure. Archives of Internal Medicine 153: 154–183, 1993CrossRefGoogle Scholar
  77. Kandiah D, Penny WJ, Fraser AG, Lewia MJ. A possible drug interaction between rifampicin and enalapril. European Journal of Clinical Pharmacology 35: 431–432, 1988PubMedCrossRefGoogle Scholar
  78. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. Journal of Hypertension 9 (Suppl. 2): s3–s9, 1991PubMedCrossRefGoogle Scholar
  79. Kirch W, Stroemer K, Hoog-Kamer JFW, Kleinbloesem CH. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril. British Journal of Clinical Pharmacology 27 (Suppl. 2): 297s–301s, 1989PubMedCrossRefGoogle Scholar
  80. Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand U-W. Clinical pharmacology of cilazapril. Drugs 41 (Suppl. 1): 3–10, 1991PubMedCrossRefGoogle Scholar
  81. Kloke HJ, Huysmans FThM, Wetzeis JFM, Sluiter HE, Kleinbloesem CH, et al. Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure. British Journal of Clinical Pharmacology 27: 289s–296s, 1989PubMedCrossRefGoogle Scholar
  82. Koch KM, Hichens M, Cirillo VJ, Gress MH, Gomez HJ, et al. The effect of probenecid on enalapril pharmacokinetics. Abstract. Pharmacological Research 5 (Suppl): S176, 1988Google Scholar
  83. Kochak GM, Rakhit A, Thompson TN, Hurley ME. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. Journal of Clinical Pharmacology 28: 222–227, 1988PubMedGoogle Scholar
  84. Koopmans PP, van Megen T, Thien T, Gribnau FWJ. The influence between indomethacin and captopril or enalapril in healthy volunteers. Journal of Internal Medicine 226: 139–142, 1989PubMedCrossRefGoogle Scholar
  85. Kripalani KJ, Mckinstry DN, Singhvi SM, Willard DA, Vukovich RA, et al. Disposition of captopril in normal subjects. Clinical Pharmacology and Therapeutics 27: 636–641, 1980PubMedCrossRefGoogle Scholar
  86. Kromer EP, Eisner D, Riegger GAJ. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure function class II and sinus rhythm. Journal of Cardiovascular Pharmacology 16: 9–14, 1990PubMedCrossRefGoogle Scholar
  87. Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. Clinical Pharmacokinetics, 10: 377–391, 1985PubMedCrossRefGoogle Scholar
  88. Leary WP, Reyes AJ. Angiotensin-I converting enzyme inhibitors and the renal excretion of urate. Cardiovascular Drugs and Therapy 1: 29–38, 1987PubMedCrossRefGoogle Scholar
  89. Lees KR, Meredith PA, Reid JL. A clinical pharmacological study of nifedipine and lisinopril alone and in combination. Journal of Cardiovascular Pharmacology 10 (Suppl. 10): sl05–sl07, 1987Google Scholar
  90. Lees KR, Reid JL. Lisinopril and nifedipine: no acute interaction in normotensives. British Journal of Clinical Pharmacology 25: 307–313, 1988PubMedCrossRefGoogle Scholar
  91. Lcijten PAAA, Willard DA, Manning J, Ivashkiv E, Jemal M. Absence of pharmacokinetic interaction between captopril and digoxin in healthy subjects, in press, 1988; cited in Duchin et al., Clinical Pharmacokinetics 14: 241–259, 1988CrossRefGoogle Scholar
  92. Levinson B, Sugerman AA, McKown J. Lack of kinetic interaction of captopril and procainamide (PA) in healthy subjects. Journal of Clinical Pharmacology 25: 460, 1985Google Scholar
  93. Levinson B, Sugerman AA, Stern M, Waclawski A, Manning J. Lack of kinetic interaction of captopril and allopurinol in healthy subjects. Abstract. In Proceedings of the American Society of Hypertension (New York), p. 129, American Society of Hypertension, New York, 1987Google Scholar
  94. Litter C, McConachie I, Healy TEJ. Interaction between enalapril and propofol. Anesthesia and Intensive Care 17: 514–515, 1989Google Scholar
  95. MacDonald TM, Craig K, Watson ML. Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man. British Journal of Clinical Pharmacology 28: 683–694, 1989PubMedCrossRefGoogle Scholar
  96. MacDonald TM, Jeffrey RF, Freestone S, Lee MR. A single dose study of the effects of fenoldopam and enalapril in mild hypertension. European Journal of Clinical Pharmacology 40: 231–236, 1991PubMedCrossRefGoogle Scholar
  97. Magelli C, Bassein L, Ribani MA, Liberatore S, Ambrosioni E, et al. Lack of effect of captopril on serum digoxin in congestive heart failure. European Journal of Clinical Pharmacology 36: 99–100, 1989PubMedCrossRefGoogle Scholar
  98. Magrini F, Shimizu M, Roberts N, Fouad FM, Tarazi RC, et al. Converting enzyme inhibition and coronary blood flow. Circulation 75 (Suppl. 1): I–168–I–174, 1987Google Scholar
  99. Mahieu M, Houvenagel E, Leduc JJ, Choteau P. Lithium-inhibiteurs de l’enzyme de conversion: une association à éviter? Presse Médicale 17: 281, 1988Google Scholar
  100. Malini PL, Strocchi E, Ambrosioni E. Simvastatin and enalapril in the treatment of hypercholesterolemic hypertensive patients. Arquivos Brasileiros de Cardiologia 53 (Suppl. 1): 190, 1989Google Scholar
  101. Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. International Journal of Clinical Pharmacology Therapy and Toxicology 22: 626–629, 1984Google Scholar
  102. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. American Journal of Physiology 261: R690–R696, 1991PubMedGoogle Scholar
  103. Matsukawa T, Gotoh E, Miyajima E, Yamada Y, Shionoiri H, et al. Angiotensin II inhibits baroreflex control of muscle sympathetic nerve activity and the heart rate in patients with essential hypertension. Journal of Hypertension 6 (Suppl. 4): s501–s504, 1988PubMedGoogle Scholar
  104. McConachie I, Healy TEJ. ACE inhibitors and anesthesia. Postgraduate Medical Journal 65: 273–274, 1989PubMedCrossRefGoogle Scholar
  105. McKenzie AJ. Possible interaction between SPPS and enalapril. Anesthesia and Intensive Care 18: 124–126, 1990Google Scholar
  106. McLean AJ, Drummer OH, Smith HJ, Froomes P, McNeil JJ. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. Journal of Human Hypertension 3: 147–151, 1989PubMedGoogle Scholar
  107. Mehta N, Modi N. ACE inhibitors in pregnancy. Lancet 2: 96, 1989CrossRefGoogle Scholar
  108. Minamisawa K, Shionoiri H, Sugimoto K, Ueda S, Ashino K, et al. Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function. Cardiovascular Drugs and Therapy 4: 1417–1424, 1990PubMedCrossRefGoogle Scholar
  109. Miyakawa T. Shionoiri H, Takasaki I, Kobayashi K, Ishii M. The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. Journal of Cardiovascular Pharmacology 17: 576–580, 1991PubMedCrossRefGoogle Scholar
  110. Miyazaki N. Shionoiri H, Uneda S, Yasuda G, Gotoh E, et al. Blood concentration and urinary excretion of captopril (SQ 14225), angiotensin converting activity and R-A-A system after administration of captopril in patients with chronic renal failure compared with essential hypertension. Japanese Journal of Nephrology 24: 421–428, 1982PubMedGoogle Scholar
  111. Mollace V, Salvemini D, Sessa WC, Vane JR. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols. Journal of Pharmacology and Experimental Therapeutics 258: 820–823, 1991PubMedGoogle Scholar
  112. Muhlberg W, Weiser K, Jakob S, Mutschier E, Platt D. Der Ein-fluss von Hydrochlorothiazide auf die Pharmakokinetik und Pharmakodynamik von Enalapril bei geriatrischen Patienten. Abstract. Klinische Wochenschrift 69 (Suppl. 23): 163, 1991Google Scholar
  113. Murray BM, Venuto RC, Kohli R, Cunningham EE. Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine. American Journal of Kidney Diseases 16: 66–69, 1990PubMedGoogle Scholar
  114. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, et al. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. Journal of the American College of Cardiology 17: 467–473, 1991PubMedCrossRefGoogle Scholar
  115. Navis GJ, de Jong PE, de Zeeuw. Volume homeostasis, angiotensin converting enzyme inhibition, and lithium therapy. American Journal of Medicine 86: 621, 1989PubMedCrossRefGoogle Scholar
  116. Nicholls MG, Gilchrist NL. Sulindac and cough induced by converting enzyme inhibitors. Lancet 1: 872, 1987PubMedGoogle Scholar
  117. Nilsen OG, Sellevold OFM, Romfo OS, Smedsrud A, Grynne B, et al. Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients. British Journal of Clinical Pharmacology 27: 323s–328s, 1989PubMedCrossRefGoogle Scholar
  118. Noormohamed FH, McNabb WR, Lant AF. Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. Journal of Pharmacology and Experimental Therapeutics 253: 362–368, 1990PubMedGoogle Scholar
  119. Nuttall A, Snow HM. The cardiovascular effects of ICI 118587: a beta-1 adrenoceptor partial agonist. British Journal of Pharmacology 77: 381–388, 1982PubMedCrossRefGoogle Scholar
  120. Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hora S, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clinical Pharmacokinetics 24: 421–427, 1993PubMedCrossRefGoogle Scholar
  121. Öhman PK, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): s20–s24, 1985PubMedCrossRefGoogle Scholar
  122. Ohyama Y, Shionoiri H, Takasaki I, Ebina T, Sugimoto K, et al. Echocardiographic assessment of the effects of short-term treatment with SQ29,852 on cardiac function in patients with essential hypertension. Asian-Pacific Symposium on ACE Inhibitors, Hong Kong, February 17–20, 1993. Abstract, p. 69, 1993Google Scholar
  123. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors on angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444, 1977PubMedCrossRefGoogle Scholar
  124. Onoyama K, Hirakata H, Iseki K, Fujimi S, Omae T, et al. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 3: 456–459, 1981PubMedCrossRefGoogle Scholar
  125. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic haemodialysis patients. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): s27–s30, 1989PubMedCrossRefGoogle Scholar
  126. Oochi N, Onoyama K, Inenaga T, Hirakata H, Oh Y, et al. The effect of a new antiestrogenic steroid, mepitiostane, on anemia in maintenance haemodialysis patients. Current Therapeutic Research 42: 17–24, 1987Google Scholar
  127. Opie LH. Reperfusion injury and its pharmacological modification. Circulation 80: 1049–1062, 1989PubMedCrossRefGoogle Scholar
  128. Opie LH. ACE inhibitors: specific agents and pharmacokinetics. In Opie (Ed.) Angiotensin converting enzyme inhibitors, pp. 149–193, Author’s Publishing House, New York. 1992Google Scholar
  129. Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. Journal of the American College of Cardiology 12: 1299–1317, 1988PubMedCrossRefGoogle Scholar
  130. Packer M, Kukin ML, Neuberg GW, Pinky DJ, Penn J, et al. The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. Journal of Hypertension 7 (Suppl. 5): 33–36, 1989Google Scholar
  131. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patters of response during long-term captopril therapy for severe chronic heart failure. Circulation 68: 803–812, 1983PubMedCrossRefGoogle Scholar
  132. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. British Medical Journal 297: 1086–1091, 1988PubMedCrossRefGoogle Scholar
  133. Pasnisi F, Elliott HL, Reid JL. Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine. Journal of Cardiovascular Pharmacology 7: 1171–1175, 1985CrossRefGoogle Scholar
  134. Pennell DJ, Nunan TO, O’Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet 1: 463, 1984PubMedCrossRefGoogle Scholar
  135. Pfeffer MA, Braunwald E, Moye LA, Basta L. Brown Jr EJ, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 327: 669–677, 1992PubMedCrossRefGoogle Scholar
  136. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988PubMedCrossRefGoogle Scholar
  137. Pollare T, Lithel H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. New England Journal of Medicine 321: 868–873, 1989PubMedCrossRefGoogle Scholar
  138. Pouleur H, Hanet C, Rousseau MF. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure with ACE-inhibitors. British Journal of Clinical Pharmacology 28: 82s–83s, 1989PubMedCrossRefGoogle Scholar
  139. Pouleur H, Rousseau MF, Oakly C, Rydén L, for the Xamoterol in Severe Heart Failure Study Group. Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure study. American Journal of Cardiology 68: 71–74, 1991PubMedCrossRefGoogle Scholar
  140. Pulik M, Lida H. Interaction lithium-inhibiteurs de l’enzyme de conversion. Presse Médicale 17: 755, 1988Google Scholar
  141. Radley AS, Fitzpatrick RW. An evaluation of the potential interaction between enalapril and amiloride. Journal of Clinical Pharmacy Therapeutics 12: 319–323, 1987CrossRefGoogle Scholar
  142. Rakhit A, Kochak GM, Tipnis V, Hurley ME. Inhibition of renal clearance of furosemide by pentopril, an angiotensin converting enzyme inhibitor. Clinical Pharmacology and Therapeutics 41: 580–586, 1987PubMedCrossRefGoogle Scholar
  143. Raskin R. How to treat hypertension in diabetic patients. Postgraduate Medicine 83: 213–232, 1988PubMedGoogle Scholar
  144. Rett K, Wicklmayr M, Dietze GJ. Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. New England Journal of Medicine 319: 1609, 1988PubMedGoogle Scholar
  145. Richer C, Bah M, Cadilhac M, Thuillez C, Giudicelli JF. Cimetidine does not alter free unchanged captopril pharmacokinetics and biological effects in healthy volunteers. Pharmacologie (Paris) 17: 338–342, 1986Google Scholar
  146. Rouleau JL, Chatterjee K, Benge W, Parmley WW, Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine, and prazosin in chronic ischemic heart failure: a comparative study. Circulation 65: 671–678, 1982PubMedCrossRefGoogle Scholar
  147. Rousseau MF, Rouleau JL, Vincent MF. Effects of a cardioselective beta-1 partial agonist (Corwin) with previous myocardial infarction. American Journal of Cardiology 51: 1267–1274, 1983PubMedCrossRefGoogle Scholar
  148. Sahloul MZ, al-Kiek R, Ivanovich P, Mujais SK. Nonsteroidal anti-inflammatory drugs and antihypertensives. Nephron 56: 345–352, 1990PubMedCrossRefGoogle Scholar
  149. Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. Journal of Hypertension 5 (Suppl. 4): S139–S142, 1987PubMedCrossRefGoogle Scholar
  150. Samanta A, Burden AC. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol. Lancet 1: 679, 1984PubMedCrossRefGoogle Scholar
  151. Sato T, Takeshi M, Baba S, Miyashita H. The interactions of digitalis-calcium antagonists and digitalis-angiotensin converting enzyme inhibitors (ACEI). Abstract. Japanese Journal of Medicine 27: 481, 1988Google Scholar
  152. Scanferla F, Toffoletto PP, Roncali D, Bazzato G. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension 4: 868, 1991PubMedGoogle Scholar
  153. Schwartz JB, Taylor A, Abernethy D, O’Meara M, Farmer J, et al. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. Journal of Cardiovascular Pharmacology 7: 767–776, 1985PubMedCrossRefGoogle Scholar
  154. Schwartz JI, Moura RL. Severe depersonalization and anxiety associated with indomethacin. Southern Medical Journal 76: 679–680, 1983PubMedCrossRefGoogle Scholar
  155. Sedman AJ. Cimetidine drug interaction. American Journal of Medicine 76: 109–114, 1984PubMedCrossRefGoogle Scholar
  156. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. Southern Medical Journal 83: 1144–1148, 1990PubMedCrossRefGoogle Scholar
  157. Sessano P, Chatellier G, Billaud E, Corvol P, Menard J. Comparison of increase in the dose and addition of hydrochrolothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone. Journal of Cardiovascular Pharmacology 13: 314–319, 1989CrossRefGoogle Scholar
  158. Shionoiri H, Gotoh E, Miyazaki N, Yasuda G, Takagi N, et al. Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension. Japanese Circulation Journal 49: 46–51, 1985aPubMedCrossRefGoogle Scholar
  159. Shionoiri H, Gotoh E, Takagi N, Takeda K, Yabana M, et al. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. Journal of Cardiovascular Pharmacology 11: 242–249, 1988PubMedGoogle Scholar
  160. Shionoiri H, Iino S, Inoue S. Glucose metabolism during captopril mono- and combination therapy in diabetic hypertensive patients. Clinical and Experimental Hypertension Part A 9: 675–679, 1987aGoogle Scholar
  161. Shionoiri H, Ikeda Y, Kimura K, Miyakawa T, Kaneko Y. Pharmacodynamics and pharmacokinetics of single-dose ramipril in hypertensive patients with various degrees of renal function. Current Therapeutic Research 40: 78–85, 1986aGoogle Scholar
  162. Shionoiri H, Minamisawa K, Sugimoto K, Takasaki I, Yasuda G, et al. Effects of combination therapy with ACE inhibitor and HMG-CoA reductase inhibitor on hemodynamics and metabolism of lipid and glucose in hypertensive patients with hypercholesterolaemia. Third International Symposium on ACE Inhibition, Amsterdam, March 19–23, 1993. Abstract 8A.1, 1993Google Scholar
  163. Shionoiri H, Minamisawa K, Ueda S, Abe Y, Ebina T, et al. Pharmacokinetics and antihypertensive effects of lisinopril in hypertensivc patients with normal and impaired renal function. Journal of Cardiovascular Pharmacology 16: 594–600, 1990aPubMedCrossRefGoogle Scholar
  164. Shionoiri H, Miyakawa T, Takasaki I, Ishikawa Y, Hiroto S, et al. Glucose tolerance during chronic captopril therapy in patients with essential hypertension. Journal of Cardiovascular Pharmacology 9: 160–164, 1987bPubMedCrossRefGoogle Scholar
  165. Shionoiri H, Miyazaki N, Yasuda G, Sugimoto K, Uneda S, et al. Blood concentration and urinary excretion of enalapril in patients with chronic renal failure. Japanese Journal of Nephrology 27: 1291–1297, 1985bPubMedGoogle Scholar
  166. Shionoiri H, Sugimoto K, Minamisawa K, Ueda S, Ebina T, et al. Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. Journal of Cardiovascular Pharmacology 15: 933–938, 1990bPubMedCrossRefGoogle Scholar
  167. Shionoiri H, Ueda S, Gotoh E, Ito T, Ogihara T. Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. Journal of Cardiovascular Pharmacology 16: 905–909, 1990cPubMedCrossRefGoogle Scholar
  168. Shionoiri H, Ueda S, Minamisawa K, Minamisawa M, Takasaki I, et al. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. Journal of Cardiovascular Pharmacology 20: 348–357, 1992PubMedCrossRefGoogle Scholar
  169. Shionoiri H, Yasuda G, Abe Y, Yoshimura H, Kaneko Y, et al. Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure. Clinical Nephrology 27: 65–70, 1987cPubMedGoogle Scholar
  170. Shionoiri H, Yasuda G, Ikeda A, Ohta T, Miyajima E, et al. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clinical Pharmacology and Therapeutics 41: 74–79, 1987dPubMedCrossRefGoogle Scholar
  171. Shionoiri H, Yasuda G, Sugimoto K, Miyazaki N, Miyakawa T, et al. The antihypertensive effect and the pharmacokinetic profile of captopril retard (CS-522-R) in patients with essential hypertension. Japanese Journal of Nephrology 28: 73–78, 1986bPubMedGoogle Scholar
  172. Shionoiri H, Yasuda G, Takagi N, Oda H, Young SC, et al. Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. Clinical and Experimental Hypertension Part A 9: 543–549, 1987cCrossRefGoogle Scholar
  173. Sica DA, Cutler RE, Parmer RJ, Ford NF, Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clinical Pharmacokinetics 20: 420–427, 1991PubMedCrossRefGoogle Scholar
  174. Singer DRJ, Markandu ND, Shore AC, MacGregor GA. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 9: 629–633, 1987PubMedCrossRefGoogle Scholar
  175. Singhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH. Renal handling of captopril: effect of probenecid. Clinical Pharmacology and Therapeutics 32: 182–189, 1982aCrossRefGoogle Scholar
  176. Singhvi SM, McKinstry DN, Shaw SM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. Journal of Clinical Pharmacology 22: 135–140, 1982bPubMedGoogle Scholar
  177. SOLVD Investigators. Effect of enarapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325: 293–302, 1991CrossRefGoogle Scholar
  178. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, et al. Two putative centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proceedings of the National Academy of Sciences of the United States of America 85: 9386–9390, 1988PubMedCrossRefGoogle Scholar
  179. Sugimoto K. Kumagai Y, Tateishi T, Seguchi H, Ebihara A. Effects on autonomie function of a new angiotensin converting enzyme inhibitor, ramipril. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): s40–s45. 1989PubMedCrossRefGoogle Scholar
  180. Suzuki H. Kawaratani T, Shioya H, Uji Y, Saruta T. Study on pharmacokinetics and blood pressure lowering effects of a biliary excreted angiotensin converting enzyme inhibitor, CS-622: seven days serial administration study. Rinsho Iyaku 8: 271–279, 1992Google Scholar
  181. Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T. Study on pharmacokinetics of a nre biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharmaceutics and Drug Disposition 14: 41–51, 1993CrossRefGoogle Scholar
  182. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, et al. Effect of captopril on heavy proteinuria in azotemic diabetes. New England Journal of Medicine 313: 1617–1620, 1985PubMedCrossRefGoogle Scholar
  183. Takasaki I, Shionoiri H, Hiroto S, Yasuda G, Gotoh E, et al. Long-term captopril therapy with no effect on glucose metabolism in patients with essential hypertension. American Journal of Hypertension 1: 217s–220s, 1988PubMedGoogle Scholar
  184. Takasaki I, Shionoiri H, Ohyama Y, Ebina T, Sugimoto K, et al. Effects of SQ29,852 on pharmacokinetics, hemodynamics and renal function in patients with essential hypertension. Hypertension 21: 572, 1993Google Scholar
  185. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–246, 1986PubMedCrossRefGoogle Scholar
  186. Toussaint C, Masselink A, Gentges A, Wambach G, Boenner G. Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide. Klinische Wochenschrift 67: 1138–1146, 1989PubMedCrossRefGoogle Scholar
  187. Townsend R, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Archives of Internal Medicine 150: 1175–1183, 1990PubMedCrossRefGoogle Scholar
  188. VA Cooperative Study Group on Antihypertensive Agents. Captopril: evaluation of low doses, twice daily doses, and the addition of diuretic for the treatment of mild to moderate hypertension. Clinical Science 63: 443s–445s, 1982Google Scholar
  189. Vandenburg MJ, Kelly JG, Wiseman WT, Mannering D, Long C, et al. The effect of lisinopril on digoxin pharmacokinetics in patients with congestive heart failure. Proceedings of the British Pharmacological Society, London, January 6–8, 1988, Abstract, pp. 656–657, 1988aGoogle Scholar
  190. Vandenburg MJ, Morris F, Marks C, Kelly JG, Dews IM, et al. A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. Xenobiotica 18: 1179–1184, 1988bPubMedCrossRefGoogle Scholar
  191. Vandenburg MJ, Stephens JD, Dews IM, Robinson P, Resplandy G, et al. Lack of pharmacokinetic interaction between digoxin and perindopril after chronic treatment of patients with congestive heart failure. Abstract. Journal of Clinical Pharmacology 30: 858, 1990Google Scholar
  192. van der Woude FJ, van Son WJ, Tegzess AM, Donker AJ, Slooff MJ, et al. Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis. Nephron 39: 184–188, 1985PubMedCrossRefGoogle Scholar
  193. van Gilst WH, de Graeff PA, de Leeuw MJ, Scholtens E, Wesseling H. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. Journal of Cardiovascular Pharmacology 18: 429–436, 1991PubMedCrossRefGoogle Scholar
  194. Van Hecken AM, Verbesselt R, Buntinx A, Cirillo VJ, De Schepper PJ. Absence of a pharmacokinetic interaction between enalapril and frusemide. British Journal of Clinical Pharmacology 23: 84–87, 1987PubMedCrossRefGoogle Scholar
  195. Verho M, Malerczyk V, Groetsch H, Zenbil I. Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent. Pharmacotherapeutica 5: 392–399, 1989Google Scholar
  196. Weber MA. Overview of fosinopril: a novel ACE inhibitor. Drug Investigation 3 (Suppl. 4): 3–11, 1991Google Scholar
  197. Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5 (Suppl. III): 132–138, 1983Google Scholar
  198. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild to moderate hypertensive patients. Journal of Cardiovascular Pharmacology 7: 552–555, 1985Google Scholar
  199. Weinberger MH. Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): s1–s4, 1989PubMedCrossRefGoogle Scholar
  200. Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. Clinical and Experimental Hypertension Part A 10: 119–133, 1988CrossRefGoogle Scholar
  201. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336: 1–6, 1990CrossRefGoogle Scholar
  202. Yasuda G, Shionoiri H, Kubo T, Misu Y. Presynaptic angiotensin II receptors and captopril-induced adrenergic transmission failure probably not via converting enzyme inhibition in guinea-pig pulmonary arteries. Journal of Hypertension 5 (Suppl. 2): s39–s45, 1987PubMedGoogle Scholar
  203. Young K. Enalapril and SPPS. Anesthesia and Intensive Care 18: 583, 1990Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Hiroshi Shionoiri
    • 1
  1. 1.Second Department of Internal MedicineYokohama City University School of MedicineYokohamaJapan

Personalised recommendations